Zentalis Pharmaceuticals (NasdaqGM:ZNTL) 2026 Conference Transcript

Summary of Zentalis Pharmaceuticals Conference Call Company Overview - Company: Zentalis Pharmaceuticals (NasdaqGM:ZNTL) - Focus: Development of azenosertib for platinum-resistant ovarian cancer patients with high Cyclin E1 expression Key Strategic Priorities - Primary Goal: Accelerate the development of azenosertib, focusing on patients with platinum-resistant ovarian cancer and high Cyclin E1 expression [4][6] - Current Trials: - DENALI Trial: Multi-part registration trial, currently in Part 2A with 60 patients enrolled [12][13] - ASPENOVA Trial: Phase 3 randomized trial expected to enroll patients in the first half of the year [4][13] Competitive Landscape - Market Dynamics: Increasing competition in the platinum-resistant ovarian cancer space, particularly from antibody-drug conjugates (ADCs) [5] - Differentiation of Azenosertib: - Oral administration versus infusion for ADCs - Non-chemotherapy option providing a "chemo break" for patients [6][7] Clinical Profile and Tolerability - Tolerability Data: - Azenosertib shows a manageable tolerability profile with 10% high-grade neutropenia and low-grade gastrointestinal adverse events [10][11] - Comparison with other WEE1 inhibitors indicates a favorable safety profile [9][10] - Dose Selection: - Ongoing evaluation of 300 mg and 400 mg doses in DENALI, with a decision expected in the first half of the year [12][13][17] Biomarker and Patient Selection - Cyclin E1 Expression: Approximately 50% of patients in the PROC population are expected to meet the eligibility criteria based on Cyclin E1 expression [27] - Eligibility Changes: Part 2 of DENALI has stricter eligibility criteria compared to Part 1, focusing on patients with fewer prior lines of treatment [22] Regulatory Considerations - Accelerated Approval Metrics: - Expected overall response rate (ORR) of around 30% and median duration of response of 5-6 months for accelerated approval [48][49] - ASPENOVA Design: Randomized controlled trial against standard-of-care, with a focus on the same patient population as DENALI [31][39] Future Opportunities - Combination Therapies: Potential for azenosertib to be used in combination with other therapies, including cytotoxic agents and ADCs [50] - Long-term Strategy: Zentalis may explore additional assets post-azenosertib, contingent on successful proof of concept [58] Other Important Insights - USC Study: Fully enrolled with plans to provide data, but not a top priority for the company [51][56] - Market Positioning: Zentalis aims to prioritize ovarian cancer indications while keeping options open for future developments [58]